Search
for
Sort by
Research 91–120 of 287
- Manifestaciones dermatológicas por Covid-19 y su aporte en la comprensión de la enfermedad
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- Anti-proliferative effect of terpenes on human prostate cáncer cells: natural sources and their potential role as chemopreventive agents.
- Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase
- Anticoronavirus Isoquinoline Alkaloids: Unraveling the Secrets of Their Structure–Activity Relationship
- Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
- 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
- Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia
- Free Testosterone Levels in Patients with Covid-19 and its Association with Disease Severity
- Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
- Association of androgenetic alopecia with a more severe form of COVID-19 infection
- The Association between COVID-19 Infection and Gabrin Sign: A Case-Control Study
- Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
- Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis
- SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism
- Testosterone in COVID-19: An Adversary Bane or Comrade Boon
- Molecular Mechanisms Lead to Sex-Specific COVID-19 Prognosis and Targeted Therapies
- The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19
- Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
- Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis
- Roles of steroid receptors in the lung and COVID-19
- Correlation between Androgenetic Alopecia and Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection in China
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
- Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
- MAIT Cells in COVID-19: Heroes, Villains, or Both?
- The Pathological Culprit of Neuropathic Skin Pain in Long COVID-19 Patients: A Case Series
- SARS-CoV-2 vaccination in androgen sensitive phenotypes – A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients